Author details

Full Name

Jacquie Chirgwin

Affiliation

ORCID

Career Start Year

2007

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
34384882	Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.	Ann Oncol	2021
33082214	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.	Clin Cancer Res	2021
32274665	Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.	Breast Cancer Research and Treatment	2020
31949268	Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.	Br J Cancer	2020
31769226	Outcomes of a randomized controlled trial assessing a smartphone Application to reduce unmet needs among people diagnosed with CancEr (ACE).	Cancer Medicine	2020
30967649	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.	Br J Cancer	2019
29158011	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.	Lancet Oncol	2018
30270527	The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable.	Asia-Pacific Journal of Clinical Oncology	2018
29310613	Efficacy of a telephone outcall program to reduce caregiver burden among caregivers of cancer patients [PROTECT]: a randomised controlled trial.	BMC Cancer	2018
29210140	Measuring cancer caregiver health literacy: Validation of the Health Literacy of Caregivers Scale-Cancer (HLCS-C) in an Australian population.	Health and Social Care in the Community	2018
26556210	Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options.	Supportive Care in Cancer	2016
25630765	Development of a conceptual model of cancer caregiver health literacy.	European Journal of Cancer Care	2016
27325862	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.	J Clin Oncol	2016
27217455	Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.	Journal of Clinical Oncology	2016
26208461	Unmet needs and depression among carers of people newly diagnosed with cancer.	European Journal of Cancer	2015
25078776	A prospective cohort study of the effects of adjuvant breast cancer chemotherapy on taste function, food liking, appetite and associated nutritional outcomes.	PLoS ONE	2014
22989364	Is chemotherapy dose intensity adequate in breast cancer management in the Australian healthcare setting: a retrospective analysis.	Asia-Pacific Journal of Clinical Oncology	2014
24393617	Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).	Breast	2014
24393305	Efficacy and cost-effectiveness of an outcall program to reduce carer burden and depression among carers of cancer patients [PROTECT]: rationale and design of a randomized controlled trial.	BMC Health Services Research	2014
24797446	Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives.	Asia-Pacific Journal of Clinical Oncology	2014
24797445	Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.	Asia-Pacific Journal of Clinical Oncology	2014
23148546	Aromatase inhibitors associated with knee subchondral bone expansion without cartilage loss.	Climacteric	2013
22056854	Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.	Annals of Oncology	2012
21892704	The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.	Breast Cancer Research and Treatment	2012
21839635	Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.	Breast	2011
21321298	Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.	Journal of Clinical Oncology	2011
21183347	Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.	Breast	2011
21358959	Does multidisciplinary care enhance the management of advanced breast cancer?: evaluation of advanced breast cancer multidisciplinary team meetings.	Journal of Oncology Practice	2010
18332471	Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.	Journal of Clinical Oncology	2008
17200148	Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.	Journal of Clinical Oncology	2007